MW Why this drug-research company's stock is having its worst day since 1999

By Tomi Kilgore

Icon shares plunged, as an accounting probe added to worries in the CRO sector about cancellations and the regulatory environment

Icon's stock is having its worst day since 1999, as an accounting probe added to investors' worries about contract research organizations.

Shares of Icon were plummeting on Thursday toward their worst day in decades, as the announcement of an accounting probe added to all the pressures the contract research organization sector has already been feeling.

As a result of the investigation, which the company $(ICLR)$ said it initiated in October, the company withdrew its financial guidance for 2025, saying it plans to release fourth-quarter results "on or prior to" April 30, which would be about two months later than usual.

The stock sank 36.4% toward a nine-year low in recent trading, and was headed for its worst day since the record 50.9% plunge it suffered on March 30, 1999.

Icon said Thursday that the investigation into accounting practices and controls focused primarily on how revenue was recorded from 2023 through 2025.

"While the investigation is continuing, at this time, preliminary indications are that the company's revenue in 2023 and 2024 may have been overstated by less than 2% for each fiscal year," the company said in a statement.

Icon stressed that it has found no reason to believe the actions leading to the investigation have had any impact on customers.

Mizuho analyst Ann Hynes said that, while the stock's reaction to Thursday's negative news may be "overdone," she believes it will remain an "overhang" on investor sentiment, especially given the concerns about the CRO industry in general.

Those concerns were confirmed earlier this week, when Icon rival Medpace Holdings $(MEDP)$ reported disappointing fourth-quarter results amid a spike in cancellations of contracts during the quarter. Earlier this month, rival Iqvia $(IQV)$ also said cancellations were elevated.

Icon's stock, which went public in May 1998, has now plummeted 53% so far in February, which would be worse than the record monthly decline of 48.7% in May 1999, representing a loss of about $7.3 billion in market capitalization.

Medpace shares have dropped 29% in February, while Iqvia's stock has shed 28%. The S&P 500 index SPX has slipped 0.5%.

Other factors weighing on the CRO sector are worries that a lighter regulatory touch on clinical trials and the Trump administration's push to lower drug prices would reduce demand for research and development.

These worries come after Food and Drug Administration Commissioner Marty Makary told STAT in December that for medical products being considered for approval, the FDA may cut the requirement to just one clinical study from the standard two.

Earlier this month, the government launched TrumpRx, which offers medications at lower prices to Americans willing to pay directly. That was part of the Trump administration's plan to lower drug costs, which included pressure on drugmakers and pharmacy-benefit managers, as well as tariffs on drugs made in overseas facilities.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 12, 2026 11:10 ET (16:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.